90 related articles for article (PubMed ID: 29891440)
21. Custirsen (OGX-011) combined with cabazitaxel and prednisone versus cabazitaxel and prednisone alone in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel (AFFINITY): a randomised, open-label, international, phase 3 trial.
Beer TM; Hotte SJ; Saad F; Alekseev B; Matveev V; Fléchon A; Gravis G; Joly F; Chi KN; Malik Z; Blumenstein B; Stewart PS; Jacobs CA; Fizazi K
Lancet Oncol; 2017 Nov; 18(11):1532-1542. PubMed ID: 29033099
[TBL] [Abstract][Full Text] [Related]
22. Prognostic value of seminal vesicle involvement due to prostate cancer in radical prostatectomy specimens.
Algarra R; Barba J; Merino I; Tienza A; Tolosa E; Robles JE; Zudaire J
Actas Urol Esp; 2015 Apr; 39(3):144-53. PubMed ID: 24996780
[TBL] [Abstract][Full Text] [Related]
23. Prostate-specific antigen flare induced by
Castello A; Macapinlac HA; Lopci E; Santos EB
Eur J Nucl Med Mol Imaging; 2018 Dec; 45(13):2256-2263. PubMed ID: 29785515
[TBL] [Abstract][Full Text] [Related]
24. The Effect of Time to Castration Resistance on Outcomes With Abiraterone and Enzalutamide in Metastatic Prostate Cancer.
Hung J; Taylor AR; Divine GW; Hafron JM; Hwang C
Clin Genitourin Cancer; 2016 Oct; 14(5):381-388. PubMed ID: 27157640
[TBL] [Abstract][Full Text] [Related]
25. The addition of bicalutamide 150 mg to radiotherapy significantly improves overall survival in men with locally advanced prostate cancer.
See WA; Tyrrell CJ;
J Cancer Res Clin Oncol; 2006 Aug; 132 Suppl 1():S7-16. PubMed ID: 16896884
[TBL] [Abstract][Full Text] [Related]
26. Prostate-specific antigen flare induced by cabazitaxel-based chemotherapy in patients with metastatic castration-resistant prostate cancer.
Angelergues A; Maillet D; Fléchon A; Ozgüroglu M; Mercier F; Guillot A; Le Moulec S; Gravis G; Beuzeboc P; Massard C; Fizazi K; de La Motte Rouge T; Delanoy N; Elaidi RT; Oudard S
Eur J Cancer; 2014 Jun; 50(9):1602-9. PubMed ID: 24725337
[TBL] [Abstract][Full Text] [Related]
27. Prostate-specific antigen level, stage or Gleason score: which is best for predicting outcomes after radical prostatectomy, and does it vary by the outcome being measured? Results from Shared Equal Access Regional Cancer Hospital database.
Mithal P; Howard LE; Aronson WJ; Kane CJ; Cooperberg MR; Terris MK; Amling CL; Freedland SJ
Int J Urol; 2015 Apr; 22(4):362-6. PubMed ID: 25728968
[TBL] [Abstract][Full Text] [Related]
28. Efficacy and safety of abiraterone acetate plus prednisolone in patients with early metastatic castration-resistant prostate cancer who failed first-line androgen-deprivation therapy: a single-arm, phase 4 study.
Kobayashi K; Okuno N; Arai G; Nakatsu H; Maniwa A; Kamiya N; Satoh T; Kikukawa H; Nasu Y; Uemura H; Nakashima T; Mikami K; Iinuma M; Tanabe K; Furukawa J; Kobayashi H
Jpn J Clin Oncol; 2021 Apr; 51(4):544-551. PubMed ID: 33324967
[TBL] [Abstract][Full Text] [Related]
29. Overexpression of Periostin in Tumor Biopsy Samples Is Associated With Prostate Cancer Phenotype and Clinical Outcome.
Cattrini C; Rubagotti A; Nuzzo PV; Zinoli L; Salvi S; Boccardo S; Perachino M; Cerbone L; Vallome G; Latocca MM; Zanardi E; Boccardo F
Clin Genitourin Cancer; 2018 Dec; 16(6):e1257-e1265. PubMed ID: 30170989
[TBL] [Abstract][Full Text] [Related]
30. Overall and progression-free survival with cabazitaxel in metastatic castration-resistant prostate cancer in routine clinical practice: the FUJI cohort.
Rouyer M; Oudard S; Joly F; Fizazi K; Tubach F; Jove J; Lacueille C; Lamarque S; Guiard E; Balestra A; Droz-Perroteau C; Fourrier-Reglat A; Moore N;
Br J Cancer; 2019 Dec; 121(12):1001-1008. PubMed ID: 31719685
[TBL] [Abstract][Full Text] [Related]
31. Prognostic factors influencing overall survival in de novo oligometastatic prostate cancer patients.
Rii J; Sakamoto S; Yamada Y; Takeshita N; Yamamoto S; Sazuka T; Imamura Y; Nakamura K; Komiya A; Komaru A; Fukasawa S; Nakatsu H; Akakura K; Ichikawa T
Prostate; 2020 Aug; 80(11):850-858. PubMed ID: 32501559
[TBL] [Abstract][Full Text] [Related]
32. A Territory-wide, Multicenter, Age- and Prostate-specific Antigen-matched Study Comparing Chemohormonal Therapy and Hormonal Therapy Alone in Chinese Men With Metastatic Hormone-sensitive Prostate Cancer.
Teoh JYC; Poon DMC; Lam D; Chan T; Chan MFT; Lee EKC; Law S; Chan K; Cheng NM; Lai KM; Leung CH; Ng CF
Clin Genitourin Cancer; 2019 Feb; 17(1):e203-e208. PubMed ID: 30454968
[TBL] [Abstract][Full Text] [Related]
33. Evolution and outcomes of 3 MHz high intensity focused ultrasound therapy for localized prostate cancer during 15 years.
Thüroff S; Chaussy C
J Urol; 2013 Aug; 190(2):702-10. PubMed ID: 23415962
[TBL] [Abstract][Full Text] [Related]
34. Impact of treatment on progression to castration-resistance, metastases, and death in men with localized high-grade prostate cancer.
Miller ET; Chamie K; Kwan L; Lewis MS; Knudsen BS; Garraway IP
Cancer Med; 2017 Jan; 6(1):163-172. PubMed ID: 27997745
[TBL] [Abstract][Full Text] [Related]
35. Disease progression and survival in patients with prostate carcinoma and positive lymph nodes after radical retropubic prostatectomy.
Kroepfl D; Loewen H; Roggenbuck U; Musch M; Klevecka V
BJU Int; 2006 May; 97(5):985-91. PubMed ID: 16643480
[TBL] [Abstract][Full Text] [Related]
36. Germline DNA-repair Gene Mutations and Outcomes in Men with Metastatic Castration-resistant Prostate Cancer Receiving First-line Abiraterone and Enzalutamide.
Antonarakis ES; Lu C; Luber B; Liang C; Wang H; Chen Y; Silberstein JL; Piana D; Lai Z; Chen Y; Isaacs WB; Luo J
Eur Urol; 2018 Aug; 74(2):218-225. PubMed ID: 29439820
[TBL] [Abstract][Full Text] [Related]
37. Long-term use of combined radiation therapy and hormonal therapy in the management of stage D1 prostate cancer.
Robnett TJ; Whittington R; Malkowicz SB; Brereton HD; Van Arsdalen K; Drach G; Wein AJ
Int J Radiat Oncol Biol Phys; 2002 Aug; 53(5):1146-51. PubMed ID: 12128114
[TBL] [Abstract][Full Text] [Related]
38. Real-world outcomes in patients with metastatic castration-resistant prostate cancer receiving second-line chemotherapy versus an alternative androgen receptor-targeted agent (ARTA) following early progression on a first-line ARTA in a US community oncology setting.
Oh WK; Cheng WY; Miao R; Vekeman F; Gauthier-Loiselle M; Duh MS; Drea E; Szatrowski TP
Urol Oncol; 2018 Nov; 36(11):500.e1-500.e9. PubMed ID: 30201382
[TBL] [Abstract][Full Text] [Related]
39. Stage T1c prostate cancer: a heterogeneous category with widely varying prognosis.
Hung AY; Levy L; Kuban DA
Cancer J; 2002; 8(6):440-4. PubMed ID: 12500852
[TBL] [Abstract][Full Text] [Related]
40. Influence of body mass index on biochemical outcome after permanent prostate brachytherapy.
Merrick GS; Butler WM; Wallner KE; Galbreath RW; Allen Z; Lief JH; Adamovich E
Urology; 2005 Jan; 65(1):95-100. PubMed ID: 15667872
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]